A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma

<div>(a) Immunohistochemistry evaluation of TGF-<i>β</i>3 expression in patient matched myometrium (M) and leiomyoma (L) representative specimen. (b) Quantitation of TGF-<i>β</i>3 immunostaining revealing a decrease in TGF-<i>β</i>3 expression in treated leiomyoma, as compared to placebo.</div>

BioMed Research International

fig2

Figure 2

Figure 2: A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma 